|
Oct. 15, 2020 |
|
|
Jan. 20, 2021 |
|
|
jRCT2031200156 |
Phase 2 study of BK1304 in healthy children |
|
Phase 2 study of BK1304 in healthy children |
Fuji Hideyuki |
||
The Research Foundation for Microbial Diseases of Osaka University |
||
3-1, Yamada-oka, Suita, Osaka |
||
pivotal@mail.biken.or.jp |
||
Fuji Hideyuki |
||
The Research Foundation for Microbial Diseases of Osaka University |
||
3-1, Yamada-oka, Suita, Osaka |
||
pivotal@mail.biken.or.jp |
Complete |
Oct. 01, 2020 |
||
| Oct. 01, 2020 | ||
| 120 | ||
Interventional |
||
randomized controlled trial |
||
double blind |
||
placebo control |
||
parallel assignment |
||
prevention purpose |
||
A person who has written informed consent from legal guardian and has obtained an ascent from subject |
||
History of influenza virus infection or influenza vaccination within 180 days prior to the first dose of study drug |
||
| 6age old over | ||
| 13age old not | ||
Both |
||
Prevention of influenza |
||
injection of Investigational new drug |
||
Response rate, geometric mean titer and geometric mean titer increase of nasal IgA antibody. |
||
| The Research Foundation for Microbial Diseases of Osaka University |
| Sugiura Clinic Institutional Review Board | |
| 4-4-16-301, Hon-cho, Kawaguchi-City, Saitama | |
| Approval | |
Sept. 03, 2020 |
No |
none |